DISK TO STIC REQUEST TO STIC Sequence in Case Paper Copy of Sequence Present Statement that Disk and Paper Copy are the Same 2964 CRF Entered Sequence Complies with Sequence Rules (If No see Attached Letter) CRF entered in parent Figures seen by draftsman Abstract 6 7 Oath/Declaration in file Oath/Declaration signed by all applicants Oath/Declaration includes all residences Oath/Declaration includes Foreign continuity Data Oath/Declaration includes US continuity Data **Corrected Filing Receipt Requested** Examiner - Please check to determine if the following are required: Restriction Requirement Sequences in claims not in compliance with sequence rules and may be required to search case If any of part B above are necessary, please act on and complete within 15 days.

Charles Reviewers Name

munology/Plant Pre-examination Checklist

Page 1 of 7

Pcalog

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/674,975

DATE: 06/12/2001

TIME: 11:48:47

Input Set : A:\sequence.app

Output Set: N:\CRF3\06122001\I674975.raw

```
ENTERED
      3 <110> APPLICANT: Agus, David B.
              Scheinberg, David
      5
              Zelenetz, Andrew D.
              Roberts, Wendy
      8 <120> TITLE OF INVENTION: Compositions and Methods for Active Vaccination
     10 <130> FILE REFERENCE: MSKP039US
C--> 12 <140> CURRENT APPLICATION NUMBER: US/09/674,975
C--> 13 <141> CURRENT FILING DATE: 2000-11-07
     15 <150> PRIOR APPLICATION NUMBER: 60/084,870
     16 <151> PRIOR FILING DATE: 1998-05-08
     18 <160> NUMBER OF SEQ ID NOS: 6
     20 <170> SOFTWARE: PatentIn Ver. 2.1
     22 <210> SEO ID NO: 1
     23 <211> LENGTH: 44
     24 <212> TYPE: PRT
     25 <213> ORGANISM: HUMAN
     27 <220> FEATURE:
    28 <223> OTHER INFORMATION: human CD20 fragment
     30 <400> SEQUENCE: 1
     31 Lys Ile Ser His Phe Leu Lys Met Glu Ser Leu Asn Phe Ile Arg Ala
                                             10
     34 His Thr Pro Tyr Ile Asn Ile Tyr Asn Cys Glu Pro Ala Asn Pro Ser
                     20
                                         25
                                                             30
     37 Glu Lys Asn Ser Pro Ser Thr Gln Tyr Cys Tyr Ser
                 35
    41 <210> SEQ ID NO: 2
    42 <211> LENGTH: 44
    43 <212> TYPE: PRT
    44 <213> ORGANISM: Murine
    46 <220> FEATURE:
    47 <223> OTHER INFORMATION: murine CD20 fragment
    49 <400> SEQUENCE: 2
    50 Thr Leu Ser His Phe Leu Lys Met Arg Arg Leu Glu Leu Ile Gln Thr
                                             10
    53 Ser Lys Pro Tyr Val Asp Ile Tyr Asp Cys Glu Pro Ser Asn Ser Ser
                     20
                                         25
                                                             30
    56 Glu Lys Asn Ser Pro Ser Thr Gln Tyr Cys Asn Ser
                 35
    60 <210> SEQ ID NO: 3
    61 <211> LENGTH: 79
    62 <212> TYPE: PRT
    63 <213> ORGANISM: HUMAN
    65 <220> FEATURE:
    66 <223> OTHER INFORMATION: exon VI of human CD20 gene
    68 <400> SEQUENCE: 3
    69 Val Lys Gly Lys Met Ile Met Asn Ser Leu Ser Leu Phe Ala Ala Ile
    70
                                             10
                                                                 15
```

RAW SEQUENCE LISTING DATE: 06/12/2001 PATENT APPLICATION: US/09/674,975 TIME: 11:48:47

Input Set : A:\sequence.app

Output Set: N:\CRF3\06122001\1674975.raw

```
72 Ser Gly Met Ile Leu Ser Ile Met Asp Ile Leu Asn Ile Lys Ile Ser
                20
                                    25
75 His Phe Leu Lys His Glu Ser Leu Asn Phe Ile Arg Ala His Thr Pro
78 Tyr Ile Asn Ile Tyr Asn Cys Glu Pro Ala Asn Pro Ser Glu Lys Asn
                            55
81 Ser Pro Ser Thr Gln Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu
                        70
85 <210> SEQ ID NO: 4
86 <211> LENGTH: 237
87 <212> TYPE: DNA
88 <213> ORGANISM: HUMAN
90 <220> FEATURE:
91 <223> OTHER INFORMATION: exon VI of human CD20 gene
93 <400> SEQUENCE: 4
94 gtcaaaggaa aaatgataat gaattcattg agcctctttg ctgccatttc tggaatgatt 60
95 ctttcaatca tggacatact taatattaaa atttcccatt ttttaaaaat ggagagtctg 120
96 aattttatta gagctcacac accatatatt aacatataca actgtgaacc agctaatccc 180
97 tetgagaaaa acteeceate tacceaatae tgttacagea tacaatetet gttettg
100 <210> SEQ ID NO: 5
101 <211> LENGTH: 1255
102 <212> TYPE: PRT
103 <213> ORGANISM: HUMAN
105 <220> FEATURE:
106 <223> OTHER INFORMATION: human Her2
108 <400> SEQUENCE: 5
109 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
110
                      5
                                         10
112 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
                                     25
115 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
                                 40
118 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
                             55
121 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
                                              75
                         70
124 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
                                          90
127 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
128
                100
                                    105
130 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
            115
                                120
133 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
                            135
                                                 140
136 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
                        150
                                            155
139 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
140
                    165
                                        170
142 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
```

DATE: 06/12/2001 RAW SEQUENCE LISTING TIME: 11:48:47 PATENT APPLICATION: US/09/674,975

Input Set : A:\sequence.app
Output Set: N:\CRF3\06122001\1674975.raw

1 4 2				180					185					190		
143	His	Dro	Cvc		Dro	Mot	Cvc	Luc		Sor	λrσ	Cve	Trn		Glu	Sar.
	нта	PIO	195	261	PIO	Mec	Cys	200	GIY	261	AIG	Cys	205	GIY	Giu	261
146	G	~1		0	C1 n	Com	T 011		7 ~~	The	1751	Crro		C117	C1,,	Cvc
	Ser		ASP	Cys	GIII	ser		TIII	AIG	1 111	vaı		Ата	Сту	GIY	Cys
149		210	_	_		_	215	_	m1			220	** ' -	a 1	a1	Q
	Ala	Arg	Cys	Lys	GIY		Leu	Pro	Thr	Asp		Cys	HIS	GIU	GIN	
	225					230	_	_		_	235		_		_	240
	Ala	Ala	Gly	Cys		Gly	Pro	Lys	His		Asp	Cys	Leu	Ala		Leu
155					245					250					255	_
157	His	Phe	Asn	His	Ser	Gly	Ile	Cys		Leu	His	Cys	Pro		Leu	Val
158				260					265					270		
160	Thr	Tyr	Asn	Thr	Asp	Thr	Phe	Glu	Ser	Met	Pro	Asn	Pro	Glu	Gly	Arg
161			275					280					285			
163	Tyr	Thr	Phe	Gly	Ala	Ser	Cys	Val	Thr	Ala	Cys	Pro	Tyr	Asn	Tyr	Leu
164		290					295					300				
166	Ser	Thr	Asp	Val	Gly	Ser	Cys	Thr	Leu	Val	Cys	Pro	Leu	His	Asn	Gln
167	305					310					315					320
169	Glu	Val	Thr	Ala	Glu	Asp	Gly	Thr	Gln	Arg	Cys	Glu	Lys	Cys	Ser	Lys
170					325					330					335	
172	Pro	Cys	Ala	Arg	Val	Cys	Tyr	Gly	Leu	Gly	Met	Glu	His	Leu	Arg	Glu
173		-		340					345					350		
175	Val	Arg	Ala	Val	Thr	Ser	Ala	Asn	Ile	Gln	Glu	Phe	Ala	Gly	Cys	Lys
176		_	355					360					365			
178	Lys	Ile	Phe	Gly	Ser	Leu	Ala	Phe	Leu	Pro	Glu	Ser	Phe	Asp	Gly	Asp
179	-	370		_			375					380				
181	Pro	Ala	Ser	Asn	Thr	Ala	Pro	Leu	Gln	Pro	Glu	Gln	Leu	Gln	Val	Phe
182	385					390					395					400
184	Glu	Thr	Leu	Glu	Glu	Ile	Thr	Gly	Tyr	Leu	Tyr	Ile	Ser	Ala	Trp	Pro
185					405			_	_	410					415	
187	Asp	Ser	Leu	Pro	Asp	Leu	Ser	Val	Phe	G1n	Asn	Leu	Gln	Val	Ile	Arg
188	-			420	_				425					430		
190	Gly	Arg	Ile	Leu	His	Asn	Gly	Ala	Tyr	Ser	Leu	Thr	Leu	Gln	Gly	Leu
191	_	-	435					440					445			
193	Gly	Ile	Ser	Trp	Leu	Gly	Leu	Arg	Ser	Leu	Arg	Glu	Leu	Gly	Ser	Gly
194	_	450					455					460				
196	Leu	Ala	Leu	Ile	His	His	Asn	Thr	His	Leu	Cys	Phe	Val	His	Thr	Val
	465					470					475					480
199	Pro	Trp	Asp	Gln	Leu	Phe	Arg	Asn	Pro	His	Gln	Ala	Leu	Leu	His	Thr
200		-	-		485		_			490					495	*
202	Ala	Asn	Arq	Pro	Glu	Asp	Glu	Cys	Val	Gly	Glu	Gly	Leu	Ala	Cys	His
203			_	500		-		-	505	_		_		510	-	
205	Gln	Leu	Cvs	Ala	Arq	Gly	His	Cys	Trp	Gly	Pro	Gly	Pro	Thr	Gln	Cys
206			515		-	-		520	-	-		_	525			
	Val	Asn	Cvs	Ser	Gln	Phe	Leu	Arg	Gly	Gln	Glu	Cys	Val	Glu	Glu	Cys
209		530	4	-			535	-	*			540				-
	Arg		Leu	Gln	Glv	Leu		Arq	Glu	Tyr	Val		Ala	Arq	His	Cys
	545				1	550		ر -			555				_	560
	Leu	Pro	Cvs	His	Pro		Cys	Gln	Pro			Glv	Ser	Val	Thr	
215			010		565		-1-			570		1			575	4
					202					5,0						

DATE: 06/12/2001 TIME: 11:48:47 RAW SEQUENCE LISTING PATENT APPLICATION: US/09/674,975

Input Set : A:\sequence.app
Output Set: N:\CRF3\06122001\I674975.raw

	Phe	Gly	Pro		Ala	Asp	Gln	Cys		Ala	Cys	Ala	His		Lys	Asp
218		_		580	1	- 1	_	_	585	~	- 1	1	.	590	•	.
	Pro	Pro		Cys	Val	Ala	Arg		Pro	ser	GIĀ	vaı		Pro	Asp	Leu
221	0	m	595	D	+ 1.	(T)	T 0	600	Dwo	7 00	C1.,	C1.,	605	717	Cvra	Cln
	Ser	-	мес	Pro	TTE	ттр	615	Pne	PIO	ASP	GIU	620	СТУ	Ата	Cys	GTII
224	Pro	610	Dro	т10	A cn	Cvc		Uic	Sor	Cvc	Va 1		Τ.Δ.1	λen	Aen	T.v.c
	625	Cys	PIO	TIE	ASII	630	1111	птэ	Ser	Cys	635	rsb	пец	дор	чэр	640
	Gly	Cve	Pro	Δla	Glu		Ara	Δla	Ser	Pro		Thr	Ser	Tle	Tle	
230		CID	110	1114	645	01			001	650					655	
	Ala	Val	Val	Glv	-	Leu	Leu	Val	Val		Leu	Gly	Val	Val	Phe	Gly
233				660					665			-		670		_
235	Ile	Leu	Ile	Lys	Arg	Arg	Gln	Gln	Lys	Ile	Arg	Lys	Tyr	Ťhr	Met	Arg
236			675					680					685			
238	Arg	Leu	Leu	Gln	Glu	Thr	Glu	Leu	Val	Glu	Pro	Leu	Thr	Pro	Ser	Gly
239		690					695					700				
	Ala	Met	Pro	Asn	Gln		Gln	Met	Arg	Ile		Lys	Glu	Thr	Glu	
	705		_		_	710		_			715				_	720
	Arg	Lys	Val	Lys		Leu	GLY	Ser	GLY		Pne	GTĀ	Thr	vaı		ьys
245	a 1	T1.	· · · · · ·	т1.	725	7	01	<i>α</i> 1	7	730	Trra	т1-	Dro	Wa 1	735	Tlo
	Gly	11e	тгр	740	Pro	ASP	СТУ	GIU	745	Val	гуѕ	TTE	PIO	750	нта	TIE
248	Lys	Wa 1	T.O.I		Glu	Δen	Thr	Ser		T.vc	Δla	Δsn	T.vs		Tle	T.e.11
251	цуз	vui	755	nig	Olu	11511	1111	760	110	1,5	· · · · ·		765	Olu		200
	Asp	Glu		Tyr	Val	Met	Ala		Val	Gly	Ser	Pro		Val	Ser	Arg
254	-	770		-		•	775	-		-		780	-			-
256	Leu	Leu	Gly	Ile	Cys	Leu	Thr	Ser	Thr	Val	Gln	Leu	Val	Thr	Gln	Leu
	785					790					795					800
	Met	Pro	Tyr	Gly		Leu	Leu	Asp	His		Arg	Glu	Asn	Arg		Arg
260					805	_	_	_	_	810			- 1	- 1	815	a 1
	Leu	Gly	Ser		Asp	Leu	Leu	Asn		Cys	Met	GIn	lle		Lys	GLY
263	14 - A		m	820	C1	7 ~ ~	17.01	7	825	17.5.7	TT 4 C	7 ~~	7 an	830	7 1 a	712
266	Met	ser	835	Leu	GIU	ASP	vai	840	Leu	vai	ULS	AIG	845	цец	ніа	нта
	Arg	Δsn		T.e.u	Val	Lvs	Ser		Asn	His	Va 1	Lvs		Thr	Asp	Phe
269	1119	850	, a i	пси	· u _	Ц	855	110		1110	, 41	860	110		or	
	Gly		Ala	Arq	Leu	Leu		Ile	Asp	Glu	Thr		Tyr	His	Ala	Asp
272	865			_		870					875					880
274	Gly	Gly	Lys	Val	Pro	Ile	Lys	Trp	Met	Ala	Leu	Glu	Ser	Ile	Leu	Arg
275					885					890					895	
277	Arg	Arg	Phe	Thr	His	Gln	Ser	Asp		${\tt Trp}$	Ser	Tyr	Gly		Thr	Val
278				900					905					910		
	${\tt Trp}$	Glu		Met	Thr	Phe	Gly		Lys	Pro	Tyr	Asp		Ile	Pro	Ala
281	_		915	_	_	_	-	920		a 2	a 3		925	D	a ?	D-: :
	Arg		Ile	Pro	Asp	Leu		GLu	Lys	GLY	GLu		ьeu	Pro	GIn	Pro
284	Dro	930	Crra	mb∽	т1 ~	7.00	935	Фтт∞	Mot	т1.	Mo+	940	Tvc	Czzc	Trn	Mo+
	Pro 945	тте	Cys	THT.	тте	950	val	TAT	Met	тте	955	vaı	ьуѕ	Cys	ттЬ	мес 960
	Ile	Aen	Ser	Glu	Cvc	-	Pro	Ara	Phe	Ara		Len	Va1	Ser	Glu	
200	110	asp.		O L U	013	*** 9	110	**** 9		9	 4	2,-u	, 41		514	

RAW SEQUENCE LISTING DATE: 06/12/2001 PATENT APPLICATION: US/09/674,975 TIME: 11:48:47

Input Set : A:\sequence.app

Output Set: N:\CRF3\06122001\I674975.raw

	.75									
230	75									
292 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln A	.SII GIU									
293 980 . 985 990	on Tou									
295 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg S	er Leu									
296 995 1000 1005										
298 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu T	yr Leu									
299 1010 1015 1020										
301 Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly A										
302 1025 1030 1035	1040									
304 Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser G										
	155									
307 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala P	ro Arg									
308 1060 1065 1070										
310 Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe A	sp Gly									
311 1075 1080 1085										
313 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro T	hr His									
314 1090 1095 1100										
316 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val P	ro Leu									
317 1105 1110 1115	1120									
319 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser P	ro Gln									
320 1125 1130 11	.35									
322 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro S	er Pro									
323 1140 1145 1150										
325 Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr L	eu Glu									
326 1155 1160 1165										
328 Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys A	sp Val									
329 1170 1175 1180										
331 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr P	ro Gln									
332 1185 1190 1195	1200									
334 Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser P	ro Ala									
335 1205 1210 12	.15									
337 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg G	ly Ala									
338 1220 1225 1230										
340 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro G	lu Tyr									
341 1235 1240 1245										
343 Leu Gly Leu Asp Val Pro Val										
344 1250 1255										
347 <210> SEO ID NO: 6										
348 <211> LENGTH: 1210										
349 <212> TYPE: PRT										
350 <213> ORGANISM: HUMAN										
352 <220> FEATURE:										
3 <223> OTHER INFORMATION: human EGFR										
355 <400> SEQUENCE: 6										
356 Met Arg Pro Ser Gly Thr Ala Gly Ala Ala Leu Leu Ala Leu L	eu Ala									
· ·	15									
359 Ala Leu Cys Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Val C										
360 20 25 30	, 5 51									
362 Gly Thr Ser Asn Lys Leu Thr Gln Leu Gly Thr Phe Glu Asp H	is Phe									
302 OI, IMI DOI NOW DID DON THE GIR BON OIL IMI THE GIR MAP II										

VERIFICATION SUMMARY

DATE: 06/12/2001

PATENT APPLICATION: US/09/674,975

TIME: 11:48:48

Input Set : A:\sequence.app

Output Set: N:\CRF3\06122001\1674975.raw

L:12 M:270 C: Current Application Number differs, Replaced Application Number L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date